ArticleAmerican journal of translational research2025
Magnesium cantharidate inhibits hepatocellular cancer by targeting RACK1.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate whether magnesium cantharidate (MC) exerts anti-hepatocellular carcinoma (anti-HCC) effects by targeting receptor for activated C kinase 1 (RACK1).
methodsThe Cancer Genome Atlas (TCGA) database was used to analyze the expression of RACK1 in liver tissues. Molecular docking was used to examine the binding interactions between MC and RACK1. Huh-7 and SK-Hep-1 liver cancer cells' viability, proliferation, and apoptosis were assessed by using the Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2'-deoxyuridine (EdU), and flow cytometry, respectively. RNA sequencing was used to explore the underlying mechanisms. Quantitative real-time PCR, immunohistochemistry, and western blotting were performed to explore the expression of key genes and proteins.
resultsTCGA analysis revealed significant upregulation of RACK1 in liver cancer tissues that was correlated with tissue type, grade, TP53 mutation, and overall survival. Molecular docking results revealed that the minimum binding energy between MC and RACK1 was -5.8 kcal/mol. Moreover, RACK1 overexpression significantly promoted cell viability and proliferation, and inhibited apoptosis in liver cancer cells. However, MC significantly reversed the viability, proliferation, and apoptosis effects induced by RACK1 overexpression in liver cancer cells. MC significantly inhibited the growth of subcutaneously transplanted tumors
conclusionMC exerts anti-HCC effects by targeting RACK1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.